By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Alder Biopharmaceuticals Inc. 

Corporate Headquarters
11804 North Creek Parkway South
Bothell  Washington  98011  U.S.A.
Phone: 425-205-2900 Fax: 425-205-2901


SEARCH JOBS

Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company committed to transforming the treatment paradigm for patients with migraine and other serious neurological or inflammatory conditions. Leveraging its pioneering monoclonal antibody technologies, Alder discovers and develops novel therapeutic antibodies designed to deliver highly differentiated, best-in-class clinical profiles. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody administered quarterly via infusion that allows for 100% of the dose available to selectively and potently inhibit the calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc.


Key Statistics


Email: info@alderbio.com
Ownership: Public

Web Site: Alder Biopharma
Employees:
Symbol: ALDR
 









Company News
Alder Biopharma Announces Closing Of Public Offering Of Common Stock 7/18/2017 10:30:50 AM
Cash-Strapped Alder Biopharma (ALDR) Secures $160 Million in Stock Sale to Continue Operations 7/14/2017 6:07:07 AM
Alder Biopharma Prices Public Offering Of Common Stock 7/13/2017 10:44:12 AM
Alder Biopharma Announces Commencement Of Public Offering Of Common Stock 7/12/2017 9:55:04 AM
Alder Biopharma's Migraine Med Hits Goals In Late-Stage Trial 6/27/2017 6:04:54 AM
Alder Biopharma To Present Migraine Prevention Data For Eptinezumab At 59th Annual Scientific Meeting Of The American Headache Society 6/8/2017 8:27:26 AM
Alder Biopharma Presents Positive Phase IIb Study Data For Eptinezumab At 69th Annual American Academy of Neurology Meeting 5/1/2017 8:10:38 AM
Alder Biopharma Announces First Quarter 2017 Financial And Operating Results 4/28/2017 8:00:53 AM
Alder Biopharma Presents Additional Data From Eptinezumab Development Program At 69th Annual American Academy of Neurology Meeting 4/24/2017 8:23:39 AM
Alder Biopharma To Host Conference Call To Discuss First Quarter 2017 Financial And Operating Results 4/20/2017 8:07:06 AM
123456789
//-->